Database for Interstitial Lung Disease

Overview

The purpose of this study is to establish a clinical database for patients bearing at risk for ILD (Interstitial Lung Disease) and to set up a prospective ILD Screening program for these patients.

Full Title of Study: “Clinical Database for the Early Recognition of Pulmonary Parenchymal Involvement in Patients With Systemic Diseases Bearing a Risk for Interstitial Lung Disease”

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Prospective
• Study Primary Completion Date: January 31, 2026

Interventions

• Diagnostic Test: chest CT
  • assessment of interstitial lung disease using chest CT

Arms, Groups and Cohorts

• prospective patient cohort
  • patients who will undergo the prospective ILD Screening algorithm
• retrospective patient cohort
  • patients with diagnosed ILD

Clinical Trial Outcome Measures

Primary Measures

• DLCO%pred (carbon monoxide diffusing capacity) at time of ILD diagnosis
  • Time Frame: 5 years
  • The investigators aim to assess DLCO% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the DLCO%pred at time of ILD diagnosis

Secondary Measures

• FVC%pred (Forced vital capacity) at time of ILD diagnosis
  • Time Frame: 5 years
  • The investigators aim to assess FVC% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the FVC%pred at time of ILD diagnosis

Participating in This Clinical Trial

Inclusion Criteria

• Age: ≥ 18 years – patients with a known systemic disease bearing a risk for ILD – signed informed consent (for prospective part) Exclusion Criteria:

• Age < 18 years – comorbidities severely limiting life-expectancy (e.g. severe cardiovascular conditions, malignant disease)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • Medical University of Graz
• Collaborator
  • Boehringer Ingelheim
• Provider of Information About this Clinical Study
  • Sponsor
• Overall Contact(s)
  • Gabor Kovacs, MD, +43-316-385, gabor.kovacs@klinikum-graz.at